{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:28Z","timestamp":1792714288517,"version":"4.5.0"},"reference-count":179,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi221441-4\"><jats:title>Importance<\/jats:title><jats:p>Patients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to treat COVID-19, evolutions of SARS-CoV-2 have been associated with monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. Thus, the therapeutic use of COVID-19 convalescent plasma has increased on the presumption that such plasma contains potentially therapeutic antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the growing number of reports of clinical experiences of patients with COVID-19 who are immunocompromised and treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-6\"><jats:title>Data Sources<\/jats:title><jats:p>On August 12, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma use in patients who are immunocompromised.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-7\"><jats:title>Study Selection<\/jats:title><jats:p>Randomized clinical trials, matched cohort studies, and case report or series on COVID-19 convalescent plasma use in patients who are immunocompromised were included. The electronic search yielded 462 unique records, of which 199 were considered for full-text screening.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 3 independent reviewers in duplicate and pooled.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-9\"><jats:title>Main Outcomes and Meaures<\/jats:title><jats:p>The prespecified end point was all-cause mortality after COVID-19 convalescent plasma transfusion; exploratory subgroup analyses were performed based on putative factors associated with the potential mortality benefit of convalescent plasma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-10\"><jats:title>Results<\/jats:title><jats:p>This systematic review and meta-analysis included 3 randomized clinical trials enrolling 1487 participants and 5 controlled studies. Additionally, 125 case series or reports enrolling 265 participants and 13 uncontrolled large case series enrolling 358 participants were included. Separate meta-analyses, using models both stratified and pooled by study type (ie, randomized clinical trials and matched cohort studies), demonstrated that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for the amalgam of both randomized clinical trials and matched cohort studies (risk ratio [RR], 0.63 [95% CI, 0.50-0.79]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221441-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest that transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.50647","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T16:32:29Z","timestamp":1673541149000},"page":"e2250647","source":"Crossref","is-referenced-by-count":150,"title":["COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis"],"prefix":"10.1001","volume":"6","author":[{"given":"Jonathon W.","family":"Senefeld","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Mengoli","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cruciani","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zani","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Gorman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[{"name":"North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Casadevall","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Joyner","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"zoi221441r1","doi-asserted-by":"publisher","first-page":"m1036","DOI":"10.1136\/bmj.m1036","article-title":"Covid-19: WHO declares pandemic because of \u201calarming levels\u201d of spread, severity, and inaction.","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"zoi221441r2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ije\/dyaa033","article-title":"The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?","volume":"49","author":"Peeri","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi221441r5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19.","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"issue":"9","key":"zoi221441r6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3390\/diagnostics11091663","article-title":"Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews.","volume":"11","author":"Franchini","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"zoi221441r7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/life11040354","article-title":"The three pillars of COVID-19 convalescent plasma therapy.","volume":"11","author":"Franchini","year":"2021","journal-title":"Life (Basel)"},{"issue":"9","key":"zoi221441r8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/vox.v116.9","article-title":"COVID-19 convalescent plasma therapy: hit fast, hit hard!","volume":"116","author":"Focosi","year":"2021","journal-title":"Vox Sang"},{"issue":"3","key":"zoi221441r9","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00200-21","article-title":"COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes.","volume":"35","author":"Focosi","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"zoi221441r10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.annonc.2021.07.015","article-title":"Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.","volume":"32","author":"Pommeret","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi221441r11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/v14020226","article-title":"Spike gene evolution and immune escape mutations in patients with mild or moderate forms of COVID-19 and treated with monoclonal antibodies therapies.","volume":"14","author":"Jary","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"zoi221441r12","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2.","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10293","key":"zoi221441r13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"zoi221441r14","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3861566","article-title":"Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta).","volume":"75","author":"Ong","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"42","key":"zoi221441r15","doi-asserted-by":"publisher","first-page":"E1619","DOI":"10.1503\/cmaj.211248","article-title":"Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada.","volume":"193","author":"Fisman","year":"2021","journal-title":"CMAJ"},{"issue":"12","key":"zoi221441r16","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/bloodadvances.2022007410","article-title":"Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.","volume":"6","author":"Li","year":"2022","journal-title":"Blood Adv"},{"key":"zoi221441r17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18540","article-title":"Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.","author":"Gachoud","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"zoi221441r18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14760584.2021.1932475","article-title":"Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.","volume":"21","author":"Focosi","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"zoi221441r19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.v61.8","article-title":"Use of convalescent plasma in COVID-19 patients with immunosuppression.","volume":"61","author":"Senefeld","year":"2021","journal-title":"Transfusion"},{"issue":"5","key":"zoi221441r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10880","article-title":"Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis.","volume":"5","author":"Khoury","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi221441r22","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research.","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"zoi221441r23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"zoi221441r24","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7414","key":"zoi221441r25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7651","key":"zoi221441r27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"24","key":"zoi221441r28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155114","article-title":"A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.","volume":"131","author":"Bar","year":"2021","journal-title":"J Clin Invest"},{"key":"zoi221441r29","article-title":"Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity: a randomized clinical trial.","author":"Denkinger","year":"2022","journal-title":"medRxiv"},{"key":"zoi221441r30","article-title":"Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial.","author":"Lacombe","year":"2022","journal-title":"medRxiv"},{"issue":"3","key":"zoi221441r31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/v13030436","article-title":"Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19.","volume":"13","author":"Biernat","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"zoi221441r32","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1097\/TP.0000000000003962","article-title":"Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis.","volume":"106","author":"Cristelli","year":"2021","journal-title":"Transplantation"},{"issue":"8","key":"zoi221441r33","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19.","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi221441r34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis.","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"key":"zoi221441r35","doi-asserted-by":"publisher","DOI":"10.1002\/hon.v40.5","article-title":"Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: an Italian retrospective study.","author":"Lanza","year":"2022","journal-title":"Hematol Oncol"},{"issue":"7","key":"zoi221441r36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/cid\/ciab647","article-title":"Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients.","volume":"74","author":"Gharbharan","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"zoi221441r37","first-page":"675","article-title":"High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients.","author":"Greenbaum","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"zoi221441r38","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/bjh.v192.6","article-title":"Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.","volume":"192","author":"Betrains","year":"2021","journal-title":"Br J Haematol"},{"key":"zoi221441r39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3129411","article-title":"COVID-19 infection clinical profile, management, outcome, and antibody response in kidney transplant recipients: a single centre experience.","volume":"2021","author":"Jasuja","year":"2021","journal-title":"Int J Nephrol"},{"issue":"3","key":"zoi221441r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103075","article-title":"Convalescent plasma therapy for severe COVID-19 in patients with hematological malignancies.","volume":"60","author":"Jeyaraman","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"14","key":"zoi221441r41","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1080\/10428194.2021.1966782","article-title":"COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.","volume":"62","author":"Levy","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"zoi221441r42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/23744235.2021.2013528","article-title":"Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.","volume":"54","author":"Ljungquist","year":"2021","journal-title":"Infect Dis (Lond)"},{"issue":"10","key":"zoi221441r43","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.","volume":"101","author":"Magyari","year":"2022","journal-title":"Ann Hematol"},{"issue":"22","key":"zoi221441r44","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1002\/cam4.v9.22","article-title":"Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients.","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"zoi221441r45","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00030-6","article-title":"Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.","volume":"2","author":"Rodionov","year":"2021","journal-title":"Lancet Microbe"},{"issue":"1","key":"zoi221441r46","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001268","article-title":"Outcomes of SOT recipients with COVID-19 in different eras of COVID-19 therapeutics.","volume":"8","author":"Sait","year":"2021","journal-title":"Transplant Direct"},{"issue":"5","key":"zoi221441r47","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hon.v39.5","article-title":"Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.","volume":"39","author":"Weinbergerova","year":"2021","journal-title":"Hematol Oncol"},{"issue":"20","key":"zoi221441r48","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"issue":"1","key":"zoi221441r49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.hemonc.2020.09.002","article-title":"Bronchoalveolar lavage-based COVID-19 testing in patients with cancer.","volume":"14","author":"Abid","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"11","key":"zoi221441r50","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246308","article-title":"Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use.","volume":"14","author":"Adedoyin","year":"2021","journal-title":"BMJ Case Rep"},{"key":"zoi221441r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e00888","article-title":"Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.","volume":"21","author":"Antony","year":"2020","journal-title":"IDCases"},{"issue":"7","key":"zoi221441r52","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer.","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"issue":"6","key":"zoi221441r53","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1097\/IPC.0000000000001004","article-title":"Recovery from COVID-19 pneumonia in a heart transplant recipient: a case report.","volume":"29","author":"Bakhsh","year":"2021","journal-title":"Infect Dis Clin Pract (Baltim, Md)"},{"issue":"1","key":"zoi221441r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102983","article-title":"SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.","volume":"60","author":"Balashov","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"16","key":"zoi221441r55","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.3390\/ijms22168902","article-title":"Clearance of the SARS-CoV-2 virus in an immunocompromised patient mediated by convalescent plasma without B-cell recovery.","volume":"22","author":"Basheer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"zoi221441r56","first-page":"273","article-title":"Successful pulsed methylprednisolone and convalescent plasma treatment in a case of a renal transplant recipient with COVID-19 positive pneumonia: a case report.","volume":"38","author":"Bayrak","year":"2021","journal-title":"Pan Afr Med J"},{"key":"zoi221441r57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721738","article-title":"Case report: convalescent plasma therapy induced anti-SARS-CoV-2 T cell expansion, NK cell maturation and virus clearance in a B cell deficient patient after CD19 CAR T cell therapy.","volume":"12","author":"Bo\u0161njak","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"zoi221441r58","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/jmv.v94.3","article-title":"Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.","volume":"94","author":"Bronstein","year":"2022","journal-title":"J Med Virol"},{"key":"zoi221441r60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2021.100096","article-title":"Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: a case report.","volume":"12","author":"Casarola","year":"2021","journal-title":"Clin Infect Pract"},{"issue":"4","key":"zoi221441r61","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00480-21","article-title":"Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment.","volume":"6","author":"Chen","year":"2021","journal-title":"mSphere"},{"issue":"4","key":"zoi221441r62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.14218\/JCTH.2020.00061","article-title":"COVID-19 in liver transplant recipients\u2014a series with successful recovery.","volume":"8","author":"Choudhury","year":"2020","journal-title":"J Clin Transl Hepatol"},{"issue":"9","key":"zoi221441r63","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.transproceed.2020.08.042","article-title":"Coronavirus disease 2019 viremia, serologies, and clinical course in a case series of transplant recipients.","volume":"52","author":"Christensen","year":"2020","journal-title":"Transplant Proc"},{"issue":"5","key":"zoi221441r64","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102821","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.","volume":"59","author":"\u00c7inar","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"zoi221441r65","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/bjh.v190.3","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery.","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"zoi221441r66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.14740\/jh845","article-title":"COVID-19-associated pneumonia in a B-cell-depleted patient with non-hodgkin lymphoma: recovery with hyperimmune plasma.","volume":"11","author":"Colombo","year":"2022","journal-title":"J Hematol"},{"issue":"1","key":"zoi221441r67","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/s12879-021-06321-2","article-title":"Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience.","volume":"21","author":"Cusi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"zoi221441r68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.911339","article-title":"Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway.","volume":"13","author":"D\u2019Abramo","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"zoi221441r69","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.transproceed.2021.03.010","article-title":"Successful management of COVID-19 infection in 2 early post-liver transplant recipients.","volume":"53","author":"Dale","year":"2021","journal-title":"Transplant Proc"},{"issue":"9","key":"zoi221441r70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eimc.2021.01.013","article-title":"Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency\u2014three consecutive cases and review of the literature.","volume":"40","author":"Delgado-Fern\u00e1ndez","year":"2021","journal-title":"Enferm Infecc Microbiol (Engl Ed)"},{"key":"zoi221441r71","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.712603","article-title":"Case report: remdesivir and convalescent plasma in a newly acute b lymphoblastic leukemia diagnosis with concomitant Sars-CoV-2 Infection.","volume":"9","author":"Dell\u2019Isola","year":"2021","journal-title":"Front Pediatr"},{"issue":"52","key":"zoi221441r72","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028470","article-title":"Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: case reports.","volume":"100","author":"Deveci","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"zoi221441r73","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2022.043","article-title":"Management of relapsed\/refractory all with inotuzumab during COVID-19: a case report.","volume":"14","author":"Di Palma","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"zoi221441r74","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103278","article-title":"Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19\u2014a case series.","volume":"60","author":"Erber","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"zoi221441r75","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","article-title":"Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.","volume":"62","author":"Ferrari","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"zoi221441r76","doi-asserted-by":"publisher","DOI":"10.1111\/tid.v23.2","article-title":"Treatment of immunocompromised COVID-19 patients with convalescent plasma.","volume":"23","author":"Fung","year":"2021","journal-title":"Transpl Infectious Dis"},{"issue":"9","key":"zoi221441r77","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clml.2021.05.013","article-title":"Dramatic response to convalescent hyperimmune plasma in association with an extended course of remdesivir in 4 b cell-depleted non-hodgkin lymphoma patients with SARS-Cov-2 pneumonia after rituximab therapy.","volume":"21","author":"Furlan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"zoi221441r78","doi-asserted-by":"publisher","first-page":"NP1","DOI":"10.1177\/03008916211067825","article-title":"Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?","volume":"108","author":"Gattuso","year":"2021","journal-title":"Tumori"},{"issue":"2","key":"zoi221441r79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151518","article-title":"Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.","volume":"7","author":"Gordon","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"zoi221441r80","doi-asserted-by":"publisher","first-page":"304","DOI":"10.6002\/ect","article-title":"Feasibility of convalescent plasma therapy in kidney transplant recipients with severe COVID-19: a single-center prospective cohort study.","volume":"19","author":"Gupta","year":"2021","journal-title":"Exp Clin Transplant"},{"key":"zoi221441r81","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veac104","article-title":"Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual.","volume":"104","author":"Halfmann","year":"2022","journal-title":"Virus Evolution"},{"issue":"4","key":"zoi221441r82","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/idr13040077","article-title":"Convalescent plasma in a patient with protracted COVID-19 and secondary hypogammaglobulinemia due to chronic lymphocytic leukemia: buying time to develop immunity?","volume":"13","author":"Hanssen","year":"2021","journal-title":"Infect Dis Rep"},{"issue":"1","key":"zoi221441r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100164","article-title":"Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.","volume":"2","author":"Honjo","year":"2020","journal-title":"Cell Rep Med"},{"issue":"11","key":"zoi221441r85","article-title":"Burton\u2019s agammaglobulinemia and COVID-19.","volume":"12","author":"Hovey","year":"2020","journal-title":"Cureus"},{"issue":"6","key":"zoi221441r86","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1017\/ice.2021.120","article-title":"Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.","volume":"43","author":"Hughes","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"zoi221441r87","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s10875-021-00983-y","article-title":"A patient with x-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma.","volume":"41","author":"Iaboni","year":"2021","journal-title":"J Clin Immunol"},{"issue":"4","key":"zoi221441r88","doi-asserted-by":"publisher","first-page":"526","DOI":"10.14701\/ahbps.2020.24.4.526","article-title":"Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia.","volume":"24","author":"Jamir","year":"2020","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"20","key":"zoi221441r89","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.3390\/ijms222010934","article-title":"Successful treatment of persistent SARS-CoV-2 infection in a b-cell depleted patient with activated cytotoxic T and NK cells: a case report.","volume":"22","author":"Jassem","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"zoi221441r90","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.v34.9","article-title":"Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications.","volume":"34","author":"Jiang","year":"2020","journal-title":"Clin Transplant"},{"issue":"10","key":"zoi221441r91","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.jaip.2020.08.059","article-title":"Three patients with x-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.","volume":"8","author":"Jin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"zoi221441r92","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.v9.12","article-title":"Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report.","volume":"9","author":"Karaolidou","year":"2021","journal-title":"Respirol Case Rep"},{"issue":"5","key":"zoi221441r93","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.","volume":"59","author":"Karatas","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"zoi221441r94","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5414\/CN110311","article-title":"Outcomes of COVID-19-positive kidney transplant recipients: a single-center experience.","volume":"94","author":"Katz-Greenberg","year":"2020","journal-title":"Clin Nephrol"},{"key":"zoi221441r95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645989","article-title":"Case report: convalescent plasma achieves SARS-CoV-2 viral clearance in a patient with persistently high viral replication over 8 weeks due to severe combined immunodeficiency (SCID) and graft failure.","volume":"12","author":"Keitel","year":"2021","journal-title":"Front Immunol"},{"issue":"7853","key":"zoi221441r96","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection.","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"zoi221441r97","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108723","article-title":"Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.","volume":"227","author":"Kenig","year":"2021","journal-title":"Clin Immunol"},{"issue":"5","key":"zoi221441r98","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/aid.2021.0145","article-title":"Short communication: prolonged COVID-19 infection in a patient with newly diagnosed HIV\/AIDS.","volume":"38","author":"Ketels","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"zoi221441r99","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9629","article-title":"Concurrent diagnosis of acute myeloid leukemia and COVID-19: a management challenge.","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"zoi221441r100","doi-asserted-by":"crossref","DOI":"10.1101\/2021.01.10.20248871","article-title":"Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host.","author":"Khatamzas","year":"2021"},{"issue":"2","key":"zoi221441r101","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2021.101125","article-title":"Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient\u2014case report and review of literature.","volume":"31","author":"Khatri","year":"2021","journal-title":"J Mycol Med"},{"issue":"4","key":"zoi221441r102","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13685","article-title":"Convalescent plasma treatment for early post-kidney transplant acquired COVID-19.","volume":"23","author":"Kluger","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"zoi221441r103","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/eji.v51.10","article-title":"Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.","volume":"51","author":"Kremer","year":"2021","journal-title":"Eur J Immunol"},{"issue":"1","key":"zoi221441r104","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-020-00968-1","article-title":"Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.","volume":"13","author":"Lancman","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"zoi221441r105","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10875-021-01193-2","article-title":"Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency.","volume":"42","author":"Lang-Meli","year":"2022","journal-title":"J Clin Immunol"},{"issue":"10","key":"zoi221441r106","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245992","article-title":"Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant.","volume":"14","author":"Lazzari","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"2","key":"zoi221441r107","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/19418744211050215","article-title":"Acute cerebellitis and myeloradiculitis associated with SARS-CoV-2 infection in common variable immunodeficiency-a case report.","volume":"12","author":"Lemus","year":"2022","journal-title":"Neurohospitalist"},{"issue":"5","key":"zoi221441r108","doi-asserted-by":"publisher","DOI":"10.1111\/tid.v22.5","article-title":"COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes.","volume":"22","author":"Lima","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"zoi221441r109","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1002\/jmv.v93.5","article-title":"SARS-CoV-2-specific humoral and cellular immunity in renal transplant and haemodialysis patients treated with convalescent plasma.","volume":"93","author":"Lindemann","year":"2021","journal-title":"J Med Virol"},{"issue":"2","key":"zoi221441r110","first-page":"1","article-title":"Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy.","volume":"41","author":"London","year":"2020","journal-title":"J Clin Immunol"},{"key":"zoi221441r111","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijid.2020.12.047","article-title":"Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson\u2019s disease: balancing immunosuppression.","volume":"103","author":"Lubnow","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"19","key":"zoi221441r112","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1182\/bloodadvances.2020002595","article-title":"Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.","volume":"4","author":"Luetkens","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"zoi221441r113","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/joim.v289.4","article-title":"Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.","volume":"289","author":"Madariaga","year":"2021","journal-title":"J Intern Med"},{"issue":"4","key":"zoi221441r114","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/j.athoracsur.2021.07.003","article-title":"Heart transplantation complicated by COVID-19 infection.","volume":"113","author":"Martens","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"zoi221441r115","article-title":"Management of persistent SARS-CoV-2 infection in patients with follicular lymphoma.","author":"Mart\u00ednez-Barranco","year":"2021","journal-title":"Acta Haematol"},{"key":"zoi221441r116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860891","article-title":"Persistence of SARS-CoV-2 infection in severely immunocompromised patients with complete remission b-cell lymphoma and anti-CD20 monoclonal antibody therapy: a case report of two cases.","volume":"13","author":"Mart\u00ednez-Chinchilla","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"zoi221441r117","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated b-cell immunodeficient patient with protracted coronavirus disease 2019.","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi221441r118","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/TP.0000000000003527","article-title":"Incidence and outcomes of COVID-19 in kidney and liver transplant recipients with HIV: report from the national HOPE in action consortium.","volume":"105","author":"Mehta","year":"2021","journal-title":"Transplantation"},{"key":"zoi221441r119","article-title":"Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant.","author":"Mendes-Correa","year":"2021","journal-title":"medRXiv"},{"issue":"11","key":"zoi221441r120","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3855\/jidc.13840","article-title":"Atypical course of COVID-19 in patient with Bruton agammaglobulinemia.","volume":"14","author":"Milo\u0161evic","year":"2020","journal-title":"J Infect Dev Ctries"},{"issue":"8","key":"zoi221441r121","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","article-title":"Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.","volume":"8","author":"Mira","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"zoi221441r122","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14916","article-title":"A case of COVID-19 reinfection in a liver transplant patient.","volume":"13","author":"Mohseni","year":"2021","journal-title":"Cureus"},{"issue":"7","key":"zoi221441r123","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab295","article-title":"Persistent severe acute respiratory syndrome coronavirus 2 infection in immunocompromised host displaying treatment induced viral evolution.","volume":"8","author":"Monrad","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"zoi221441r124","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927812","article-title":"A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma.","volume":"21","author":"Moore","year":"2020","journal-title":"Am J Case Rep"},{"issue":"8","key":"zoi221441r125","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244853","article-title":"High-titer convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection.","volume":"14","author":"Moutinho-Pereira","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"1","key":"zoi221441r126","doi-asserted-by":"publisher","DOI":"10.1111\/tid.v23.1","article-title":"Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy.","volume":"23","author":"Naeem","year":"2020","journal-title":"Transplant Infect Dis"},{"issue":"8","key":"zoi221441r127","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001178","article-title":"Transplant of SARS-CoV-2-infected living donor liver: case report.","volume":"7","author":"Nguyen","year":"2021","journal-title":"Transplant Direct"},{"issue":"12","key":"zoi221441r128","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41409-020-0972-8","article-title":"COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma.","volume":"55","author":"Niu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"zoi221441r129","article-title":"Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion.","author":"Nussenblatt","year":"2021","journal-title":"medRXiv"},{"issue":"1","key":"zoi221441r130","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12879-022-07323-4","article-title":"Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.","volume":"22","author":"Nystr\u00f6m","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"1","key":"zoi221441r131","first-page":"62","article-title":"Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.","volume":"45","author":"Oliva","year":"2022","journal-title":"New Microbiol"},{"issue":"1","key":"zoi221441r132","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.mayocp.2021.11.001","article-title":"Vax-plasma in patients with refractory COVID-19.","volume":"97","author":"Ordaya","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"zoi221441r133","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103104","article-title":"Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.","volume":"60","author":"Ormazabal V\u00e9lez","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"zoi221441r134","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7812\/TPP\/21.035","article-title":"Effect of immunosuppressive diseases and rituximab infusions on allowing COVID-19 infection to relapse.","volume":"26","author":"Prasad","year":"2021","journal-title":"Perm J"},{"issue":"3","key":"zoi221441r135","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s15010-022-01821-y","article-title":"Remdesivir in coronavirus disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.","volume":"50","author":"R\u00fcfenacht","year":"2022","journal-title":"Infection"},{"issue":"1","key":"zoi221441r136","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13223-021-00518-5","article-title":"Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma.","volume":"17","author":"Ribeiro","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"zoi221441r137","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","author":"Rnjak","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"zoi221441r138","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8840536","article-title":"COVID-19 coinfection with Mycobacterium abscessus in a patient with multiple myeloma.","volume":"2021","author":"Rodriguez","year":"2021","journal-title":"Case Rep Infect Dis"},{"issue":"8","key":"zoi221441r139","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00296-021-04905-4","article-title":"COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.","volume":"41","author":"Rodriguez-Pla","year":"2021","journal-title":"Rheumatol Int"},{"issue":"3","key":"zoi221441r140","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1111\/bjh.v196.3","article-title":"Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.","volume":"196","author":"Schenker","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"zoi221441r141","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytab217","article-title":"Cardiac transplant recipient with COVID-19 induced acute hypoxic respiratory failure: a case report.","volume":"5","author":"Schreiber","year":"2021","journal-title":"Eur Heart J Case Rep"},{"issue":"11","key":"zoi221441r142","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient\u2014a case study.","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi221441r143","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102956","article-title":"Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia.","volume":"60","author":"Shankar","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"zoi221441r144","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/eji.v52.2","article-title":"AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection.","volume":"52","author":"Spinicci","year":"2022","journal-title":"Eur J Immunol"},{"key":"zoi221441r145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840126","article-title":"SARS-CoV-2 T cell response in severe and fatal COVID-19 in primary antibody deficiency patients without specific humoral immunity.","volume":"13","author":"Steiner","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"zoi221441r146","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12015-020-10107-5","article-title":"Usefulness of plasma SARS-CoV-2 RNA quantification by droplet-based digital pcr to monitor treatment against COVID-19 in a b-cell lymphoma patient.","volume":"17","author":"Szwebel","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"zoi221441r147","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.","volume":"20","author":"Taha","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"zoi221441r148","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfaa166","article-title":"Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome.","volume":"13","author":"Trimarchi","year":"2020","journal-title":"Clin Kidney J"},{"key":"zoi221441r149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19.","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"zoi221441r150","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108662","article-title":"SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency.","volume":"224","author":"van Oers","year":"2021","journal-title":"Clin Immunol"},{"issue":"1","key":"zoi221441r151","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clml.2020.06.012","article-title":"Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma.","volume":"21","author":"Wright","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"zoi221441r152","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.v92.10","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.","volume":"92","author":"Ye","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"zoi221441r153","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40779-020-00273-5","article-title":"Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma.","volume":"7","author":"Zhang","year":"2020","journal-title":"Mil Med Res"},{"key":"zoi221441r154","article-title":"Convalescent plasma rescued a severe COVID-19 patient with chronic myeloid leukemia blast crisis and myelofibrosis.","author":"Zhang","year":"2020","journal-title":"Turk J Haematol"},{"key":"zoi221441r155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613502","article-title":"case report: stepwise anti-inflammatory and Anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery.","volume":"12","author":"Zimmerli","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"zoi221441r156","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.transproceed.2021.12.014","article-title":"COVID-19 in recent lung transplant recipients: clinical outcomes and management strategies.","volume":"54","author":"Zimmermann","year":"2022","journal-title":"Transplant Proc"},{"issue":"7","key":"zoi221441r157","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/v14071443","article-title":"Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients.","volume":"14","author":"Franchini","year":"2022","journal-title":"Viruses"},{"issue":"7","key":"zoi221441r158","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/life12071098","article-title":"Clinical and virological response to convalescent plasma in a chronic lymphocytic leukemia patient with COVID-19 pneumonia.","volume":"12","author":"Belcari","year":"2022","journal-title":"Life (Basel)"},{"issue":"1","key":"zoi221441r159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged SARS-CoV-2 replication in an immunocompromised patient.","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"zoi221441r160","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s10875-021-00996-7","article-title":"Resolution of persistent COVID-19 after convalescent plasma in a patient with B cell aplasia.","volume":"41","author":"McKemey","year":"2021","journal-title":"J Clin Immunol"},{"issue":"3","key":"zoi221441r161","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/tme.v31.3","article-title":"Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: a report of 17 patients.","volume":"31","author":"Pal","year":"2021","journal-title":"Transfus Med"},{"issue":"2","key":"zoi221441r162","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study.","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"zoi221441r163","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","article-title":"Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.","volume":"11","author":"Buckland","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"zoi221441r164","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41375-020-0914-x","article-title":"Response to \u201cCOVID-19 in persons with haematological cancers\u201d.","volume":"34","author":"Hatzl","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"zoi221441r165","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41375-021-01175-8","article-title":"Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.","volume":"35","author":"Reuken","year":"2021","journal-title":"Leukemia"},{"key":"zoi221441r166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103355","article-title":"Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series.","volume":"67","author":"Truong","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"zoi221441r167","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"zoi221441r168","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.v34.12","article-title":"Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City.","author":"Rahman","year":"2020","journal-title":"Clin Transplant"},{"issue":"1","key":"zoi221441r169","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/TP.0000000000003495","article-title":"COVID-19 in solid organ transplant recipients: observations from Connecticut.","volume":"105","author":"Kutzler","year":"2021","journal-title":"Transplantation"},{"issue":"11","key":"zoi221441r170","first-page":"e4020","article-title":"Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.","volume":"73","author":"Malsy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"zoi221441r171","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaip.2020.09.052","article-title":"Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City.","volume":"9","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"zoi221441r172","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"zoi221441r174","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.7326\/M22-1079","article-title":"Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma.","volume":"175","author":"Estcourt","year":"2022","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi221441r175","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03372-20","article-title":"The principles of antibody therapy for infectious diseases with relevance for COVID-19.","volume":"12","author":"Casadevall","year":"2021","journal-title":"mBio"},{"key":"zoi221441r176","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2101334","article-title":"SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: a clinical case.","volume":"2101334","author":"Mukhina","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"zoi221441r177","doi-asserted-by":"publisher","first-page":"P163","DOI":"10.1016\/j.cmi.2020.09.036","article-title":"What is the optimal usage of Covid-19 convalescent plasma donations","volume":"27","author":"Focosi","year":"2020","journal-title":"Clin Microb Infect"},{"key":"zoi221441r179","article-title":"Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources.","author":"Focosi","year":"2021","journal-title":"medRxiv"},{"key":"zoi221441r26","volume-title":"s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011"},{"key":"zoi221441r83","first-page":"4","volume-title":"Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset All","author":"Hartman","year":"2021"},{"key":"zoi221441r3","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO). Coronavirus disease (COVID-19). Accessed July 10, 2022. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019.","DOI":"10.46945\/bpj.10.1.03.01"},{"key":"zoi221441r4","unstructured":"WHO. Therapeutics and COVID-19: living guideline. Accessed August 1, 2022. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.4"},{"key":"zoi221441r21","unstructured":"Convalescent plasma EUA letter of authorization. US Food and Drug Administration. Published December 28, 2021. Accessed December 2, 2022. https:\/\/www.fda.gov\/media\/141477\/download."},{"key":"zoi221441r59","doi-asserted-by":"crossref","unstructured":"Bruiners? N, Guerrini? V, Ukey? R, . Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms.? medRxiv. 2022. doi:10.1101\/2022.02.03.22269612","DOI":"10.1101\/2022.02.03.22269612"},{"key":"zoi221441r173","unstructured":"IDSA guidelines on the treatment and management of patients with COVID-19. Infectious Disease Society of America. Accessed February 9, 2022. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/"},{"key":"zoi221441r178","unstructured":"Sample? I. Doctors treat first UK patient in COVID 'super donor 'blood trial. The Guardian. Accessed August 3, 2022. https:\/\/www.theguardian.com\/world\/2022\/jun\/30\/doctors-treat-first-uk-patient-covid-super-donor-blood-trial-antibodies"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800275\/senefeld_2023_oi_221441_1672346537.4674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T22:09:56Z","timestamp":1679350196000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":179,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50647","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}